GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » EV-to-EBITDA

Assembly Biosciences (FRA:V7B) EV-to-EBITDA : 0.50 (As of May. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Assembly Biosciences's enterprise value is €-25.80 Mil. Assembly Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-51.29 Mil. Therefore, Assembly Biosciences's EV-to-EBITDA for today is 0.50.

The historical rank and industry rank for Assembly Biosciences's EV-to-EBITDA or its related term are showing as below:

FRA:V7B' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.52   Med: -0.86   Max: 1.19
Current: 0.5

During the past 13 years, the highest EV-to-EBITDA of Assembly Biosciences was 1.19. The lowest was -19.52. And the median was -0.86.

FRA:V7B's EV-to-EBITDA is ranked better than
79.11% of 450 companies
in the Biotechnology industry
Industry Median: 9.57 vs FRA:V7B: 0.50

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Assembly Biosciences's stock price is €13.65. Assembly Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-9.703. Therefore, Assembly Biosciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Assembly Biosciences EV-to-EBITDA Historical Data

The historical data trend for Assembly Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences EV-to-EBITDA Chart

Assembly Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.96 0.01 0.31 0.26 1.15

Assembly Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 -0.03 -0.02 1.15 0.69

Competitive Comparison of Assembly Biosciences's EV-to-EBITDA

For the Biotechnology subindustry, Assembly Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's EV-to-EBITDA falls into.



Assembly Biosciences EV-to-EBITDA Calculation

Assembly Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-25.803/-51.289
=0.50

Assembly Biosciences's current Enterprise Value is €-25.80 Mil.
Assembly Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-51.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Assembly Biosciences  (FRA:V7B) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Assembly Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.65/-9.703
=At Loss

Assembly Biosciences's share price for today is €13.65.
Assembly Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.703.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Assembly Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Assembly Biosciences (FRA:V7B) Business Description

Traded in Other Exchanges
Address
331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines